药理学
体内
药代动力学
间隙
恩他卡彭
体外
邻苯二酚-O-甲基转移酶
药品
化学
医学
生物
内科学
疾病
生物化学
左旋多巴
帕金森病
生物技术
等位基因
泌尿科
基因
作者
Zhen Wang,Zhe Wang,Xiaoyu Wang,Xin Lv,Hang Yin,Xiaoyu Fan,Mingrui Yan,Yanyan Jia,Lili Jiang,Yangliu Xia,Wenli Li,Yong Liu
标识
DOI:10.1016/j.toxlet.2022.07.003
摘要
Catechol-O-methyltransferase (COMT) inhibitors are widely used as an add-on treatment to levodopa in adults with Parkinson’s disease. It has been evidenced that the second-generation COMT inhibitors entacapone and tolcapone are potent inhibitors on human UDP-glucosyltransferases (UGTs), while the effect of the third-generation COMT inhibitor opicapone on human UGTs activities is unclear. The purpose of this study is to systemically investigate the effects of opicapone on human UGTs activities, and also to assess the potential risk of drug-drug interactions (DDIs) associated with opicapone. Our results indicated that opicapone is a broad-spectrum inhibitor of UGTs. Particularly, opicapone exhibited potent inhibition against UGT1A1, 1A7, 1A8, 1A9, and 1A10, with a range of inhibition constant K i values of 1.31-10.58 µM. Furthermore, the DDI risk was quantitatively predicted by using the in vitro-in vivo extrapolation (IVIVE). The prediction suggested that co-administration of opicapone at 25 mg/day or 50 mg/day with drugs primarily cleared by hepatic UGT1A9 or intestinal UGT1A1, 1A7, 1A8, 1A9, or 1A10 might result in potential DDI via inhibition of intestinal or hepatic UGTs. • Opicapone is a potent inhibitor for UGT1A1, 1A7, 1A8, 1A9, and 1A10. • Opicapone is likely to cause a significant DDIs via inhibition of hepatic UGT1A9. • Combination of opicapone with intestinal UGTs substrates may cause clinical DDIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI